Antipsychotic prescribing patterns in Germany: A retrospective analysis using a large outpatient prescription database

International Clinical Psychopharmacology

Volumn 18, Issue 4, 2003, Pages 237-242

  Hamann, Johannes ^a   Ruppert, Andras ^b   Auby, Philippe ^c   Pugner, Klaus ^d   Kissling, Werner ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b Outcomes Res and Health Economics   (Germany)

^c BMS   (Belgium)

^d BMS   (Belgium)

Author keywords

Antipsychotics; Comedication; Prescriptions; Psychotropic drugs

Indexed keywords

AMISULPRIDE; CLOZAPINE; MELPERONE; NEUROLEPTIC AGENT; OLANZAPINE; PROMETHAZINE; QUETIAPINE; RISPERIDONE; SULPIRIDE; TRIFLUPROMAZINE; ZOTEPINE;

ADULT; ARTICLE; DATA BASE; DRUG EFFICACY; FEMALE; GERMANY; HEALTH CARE QUALITY; HUMAN; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; OUTPATIENT; PATIENT COMPLIANCE; POLYPHARMACY; PRESCRIPTION; PRIORITY JOURNAL; PSYCHOSIS; RETROSPECTIVE STUDY;

EID: 0038779754     PISSN: 02681315     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004850-200307000-00006     Document Type: Article

References (19)

1. Bahlo E, Bausch J, Brech W, Brosig A, Dabrock P, Deckert C, et al. (2001). Berliner empfehlungen. In: Dierks C (editor): Innovationen in der Therapie der Schizophrenie. Stuttgart: Schattauer, p. 77-79.
2. Clark RE, Bartels SJ, Mellman TA, Peacock WJ (2002). Recent trends in antipsychotic combination therapy of schizophrenia and schizoaffective disorder: implications for state mental health policy. Schizophr Bull 28:75-84.
3. DGPPN (1998). Behandlungsleitlinie Schizophrenie. Darmstadt: Steinkopff.
4. Dolder CR, Lacro JP, Dunn LB, Jeste DV (2002). Antipsychotic medication adherence: is there a difference between typical and atypical agents? Am J Psychiatry 159:103-108.
5. Kasper S, Rosillon D, Duchesne I (2001). Risperidone olanzapine drug outcomes studies in schizophrenia (RODOS): efficacy and tolerability results of an international naturalistic study. Int Clin Psychopharmacol 16:179-187.
6. Leucht S, Pitschel-Walz G, Abraham D, Kissling W (1999). Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials. Schizophr Res 35:51-68.
7. Linden M, Thiels C (2001). Epidemiology of prescriptions of neuroleptic drugs, tranquilizers rather than antipsychotics. Pharmacopsychiatry 34:150-154.
8. Naber D, Karow A (2001). Good tolerability equals good results: the patient's perspective. Eur Neuropsychopharmacol 11 (suppl 4):S391-S396.
9. Sernyak MJ, Leslie DL, Alarcon RD, Losonczy MF, Rosenheck R (2002). Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia. Am J Psychiatry 159:561-566.
10. Statistisches Bundesamt (1998). Gesundheitsbericht für Deutschland 1998. Wiesbaden.
11. Statistisches Bundesamt (2002). Statistisches Jahrbuch 2002 für die Bundes-republik Deutschland. Wiesbaden.
12. Svarstad BL, Shireman TI, Sweeney JK (2001). Using drug claims data to assess the relationship of medication adherence with hospitalization and costs. Psychiatr Serv 52:805-811.
13. Taylor DM (2003). Antipsychotics and QT prolongation. Acta Psychiatr Scand 107:85-95.
14. Vanelli M, Burstein P, Cramer J (2001). Refill patterns of atypical and conventional antipsychotic medications at a national retail pharmacy chain. Psychiatr Serv 52:1248-1250.
15. Waddington JL, Youssef HA, Kinsella A (1998). Mortality in schizophrenia. Antipsychotic polypharmacy and absence of adjunctive anticholinergics over the course of a 10-year prospective study. Br J Psychiatry 173:325-329.
16. Weissman EM (2002). Antipsychotic prescribing practices in the Veterans Healthcare Administration-New York metropolitan region. Schizophr Bull 28:31-42.
17. Weyerer S, Dilling H (1991). Psychiatric and physical illness, sociodemographic characteristics, and the use of psychotropic drugs in the community: results from the Upper Bavarian Field Study. J Clin Epidemiol 44:303-311.
18. WHO Collaborating Centre for Drug Statistics Methodology (1998). Guidelines for ATC Classification and DDD Assignment. Oslo: WHO.
19. World Health Association (2001). The World Health Report: 2001: Mental Health: New Understanding, New Hope. Geneva: WHO.